Exploring Weight Loss Medications for Pets: Recent Developments in Cat Clinical Trials

Weight loss drugs like the GLP-1 class, which are currently popular among humans, may soon be available for pets as well.

Okava Pharmaceuticals in San Francisco has initiated a clinical trial called MEOW-1. This study involves an implantable device designed to deliver a GLP-1 medication gradually over a six-month period in 50 cats.

The implant, named OKV-119, is intended to replicate the biological impacts of fasting. This includes enhanced insulin sensitivity, diminished body fat, and improved energy use, without necessitating major dietary changes or affecting the human-pet relationship, which often revolves around food.

According to the company, this innovation could improve the life quality and foster healthier aging in cats.

Addressing Feline Obesity

Statistics indicate that approximately 60% of cats in the U.S. are overweight.

Dr. Ernie Ward, an authority on pet obesity, notes that traditional advice such as reducing food intake and increasing activity doesn’t suit all cases of obesity.

Ward suggests that this new drug could improve general health and lower diabetes risk, similar to findings in human studies.

Anticipating the Outcomes

Ward highlights that significant uncertainties surrounding the trial include effectiveness, potential side effects, and financial implications.

Okava is targeting a monthly cost of approximately $100 for pet owners.

Savannah Tielking is a pet owner who might consider this treatment for her 21-pound cat, Runkle, especially if other options prove ineffective.

She mentioned, "He mostly lounges all day. If our vet recommends this after other attempts fail, I would definitely consider it."

The MEOW-1 trial results are anticipated by next summer, followed by applications for FDA approval, with plans to eventually expand to dogs.